Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v2.4.1.9
Consolidated Statements of Operations (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Revenues [Abstract]      
Lymphoseek sales revenue $ 4,233,953us-gaap_SalesRevenueNet $ 614,423us-gaap_SalesRevenueNet $ 0us-gaap_SalesRevenueNet
Lymphoseek milestone revenue 300,000navb_MilestoneRevenue 0navb_MilestoneRevenue 0navb_MilestoneRevenue
Grant and other revenue 1,740,896us-gaap_RevenueFromGrants 516,207us-gaap_RevenueFromGrants 78,738us-gaap_RevenueFromGrants
Total revenue 6,274,849us-gaap_Revenues 1,130,630us-gaap_Revenues 78,738us-gaap_Revenues
Cost of goods sold 1,586,145us-gaap_CostOfGoodsSold 332,815us-gaap_CostOfGoodsSold 0us-gaap_CostOfGoodsSold
Gross profit 4,688,704us-gaap_GrossProfit 797,815us-gaap_GrossProfit 78,738us-gaap_GrossProfit
Operating expenses:      
Research and development 16,779,589us-gaap_ResearchAndDevelopmentExpense 23,710,183us-gaap_ResearchAndDevelopmentExpense 16,890,482us-gaap_ResearchAndDevelopmentExpense
Selling, general and administrative 15,542,071us-gaap_SellingGeneralAndAdministrativeExpense 15,525,946us-gaap_SellingGeneralAndAdministrativeExpense 11,177,559us-gaap_SellingGeneralAndAdministrativeExpense
Total operating expenses 32,321,660us-gaap_OperatingExpenses 39,236,129us-gaap_OperatingExpenses 28,068,041us-gaap_OperatingExpenses
Loss from operations (27,632,956)us-gaap_OperatingIncomeLoss (38,438,314)us-gaap_OperatingIncomeLoss (27,989,303)us-gaap_OperatingIncomeLoss
Other income (expense):      
Interest income 16,102us-gaap_InvestmentIncomeNet 18,838us-gaap_InvestmentIncomeNet 25,044us-gaap_InvestmentIncomeNet
Interest expense (3,706,170)us-gaap_InterestExpense (2,778,780)us-gaap_InterestExpense (1,166,332)us-gaap_InterestExpense
Equity in loss of R-NAV, LLC (523,809)us-gaap_IncomeLossFromEquityMethodInvestments 0us-gaap_IncomeLossFromEquityMethodInvestments 0us-gaap_IncomeLossFromEquityMethodInvestments
Change in fair value of financial instruments (1,342,389)navb_ChangeinFairValueofFinancialInstruments (112,073)navb_ChangeinFairValueofFinancialInstruments 32,110navb_ChangeinFairValueofFinancialInstruments
Loss on extinguishment of debt (2,610,196)us-gaap_GainsLossesOnExtinguishmentOfDebt (1,372,266)us-gaap_GainsLossesOnExtinguishmentOfDebt 0us-gaap_GainsLossesOnExtinguishmentOfDebt
Other, net 72,749us-gaap_OtherNonoperatingIncomeExpense (16,863)us-gaap_OtherNonoperatingIncomeExpense (58,723)us-gaap_OtherNonoperatingIncomeExpense
Total other expense, net (8,093,713)us-gaap_NonoperatingIncomeExpense (4,261,144)us-gaap_NonoperatingIncomeExpense (1,167,901)us-gaap_NonoperatingIncomeExpense
Net loss (35,726,669)us-gaap_IncomeLossFromContinuingOperations (42,699,458)us-gaap_IncomeLossFromContinuingOperations (29,157,204)us-gaap_IncomeLossFromContinuingOperations
Preferred stock dividends 0us-gaap_PreferredStockDividendsIncomeStatementImpact 0us-gaap_PreferredStockDividendsIncomeStatementImpact (43,333)us-gaap_PreferredStockDividendsIncomeStatementImpact
Net loss attributable to common stockholders $ (35,726,669)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (42,699,458)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (29,200,537)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Net loss per common share (basic and diluted), in dollars per share $ (0.24)us-gaap_EarningsPerShareBasicAndDiluted $ (0.35)us-gaap_EarningsPerShareBasicAndDiluted $ (0.29)us-gaap_EarningsPerShareBasicAndDiluted
Weighted average shares outstanding (basic and diluted), in shares 148,748,396us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 121,808,986us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 99,059,997us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted